Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK2 | Q16620 | 2/20 | 0.56 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.56 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.56 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.56 |
| ▸ | KDR | P35968 | 2/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.54 |
| ▸ | MET | P08581 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.54 |
| ▸ | PRKACA | P17612 | 1/20 | 0.54 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.54 |
| ▸ | FLT3 | P36888 | 1/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.54 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.54 |
| ▸ | MST1R | Q04912 | 1/20 | 0.54 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.54 |
| ▸ | CAMK1D | Q8IU85 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29584703 | 1.00 | NTRK2 (0.56) | NTRK2CLK4DYRK1BTYRO3KDR | |
| SCHEMBL618639 | 0.84 | CA12 (0.53) | NTRK2CLK4DYRK1BTYRO3KDR | |
| SCHEMBL29853505 | 0.83 | CA9 (0.44) | NTRK2CLK4DYRK1BTYRO3KDR | |
| SCHEMBL26775387 | 0.83 | CA9 (0.44) | NTRK2CLK4DYRK1BTYRO3KDR | |
| SCHEMBL29438680 | 0.81 | PARP10 (0.69) | PBRM1TDP2PARP1PARP10DRD2 | |
| SCHEMBL246168 | 0.81 | PARP10 (0.69) | PBRM1TDP2PARP1PARP10DRD2 | |
| SCHEMBL391991 | 0.80 | PARP10 (0.68) | NTRK2CLK4DYRK1BTYRO3KDR | |
| SCHEMBL29506974 | 0.80 | PARP10 (0.68) | NTRK2CLK4DYRK1BTYRO3KDR | |
| SCHEMBL22451521 | 0.78 | ESR1 (0.47) | KDRCA12CA9PBRM1AURKA | |
| SCHEMBL10201434 | 0.78 | PARP1 (0.56) | PBRM1TDP2PARP1PARP10MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023077049-A1 | METHODS OF PREPARING 6-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS | TREVENA, INC. (US) | 2023-05-04 | — | — | WO | claimed |
| EP-3582779-B1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230303531-A1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | TREVENA, INC. | 2023-09-28 | — | — | US | disclosed |
| CN-110446495-B | Delta opioid receptor modulating compounds containing 7-membered aza heterocycles and methods of use and preparation thereof | 特维娜有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11702408-B2 | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | TREVENA, INC. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | WYETH (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2006138549-A1 | TRICYCLIC COMPOUNDS USEFUL AS SEROTONIN INHIBITORS AND 5-HT1A AGONISTS AND ANTAGONISTS | WYETH (US) | 2006-12-28 | — | — | WO | disclosed |
| EP-1545548-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA Pharma AG (DE) | 2005-06-29 | — | — | EP | disclosed |
| EP-1539694-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-15 | — | — | EP | disclosed |
| US-6846832-B2 | 2,3-dihydro-isoindol-1-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-01-25 | — | — | US | disclosed |
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | HOFFMANN-LA ROCHE INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004019955-A1 | THE USE OF THE COMBINATION OF CICLESONIDE AND ANTIHISTAMINES FOR THE TREATMENT OF ALLERGIC RHINITIS | ALTANA PHARMA AG (DE) | 2004-03-11 | — | — | WO | disclosed |
| WO-2004014856-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
| WO-2004014856-A1 | 2,3-DIHYDRO-ISOINDOL-1-ONES WITH MAO-B INHIBITING ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11702408-B2 | 5-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | NTRK2 854/4885CLK4 4818/4885DYRK1B 1419/4885 |
| US-11912713-B2 | 7-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same | OPRD1, OPRM1, OPRK1 | NTRK2 794/4885CLK4 4601/4885DYRK1B 1049/4885 |
| US-20070149585-A1 | Compounds useful as serotonin inhibitors and 5-HT1A agonists and antagonists | HTR1A, HTR7, HTR3A | NTRK2 387/4885CLK4 4057/4885DYRK1B 1121/4885 |
| US-20040082603-A1 | 2,3-Dihydro-isoindol-1-one derivatives | MAOB, MAOA, COMT | NTRK2 1343/4885CLK4 4356/4885DYRK1B 1365/4885 |
| US-20230303531-A1 | 5-MEMBERED AZA-HETEROCYCLIC CONTAINING DELTA-OPIOID RECEPTOR MODULATING COMPOUNDS, METHODS OF USING AND MAKING THE SAME | OPRD1, OPRM1, OPRK1 | NTRK2 859/4885CLK4 4654/4885DYRK1B 1070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.